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Abstract
To date, the improvements in survival of patients with liver metastases and
advances in technology allowed the surgical indications to be extended. In complex
cases, however, the possibility of performing a curative hepatic resection collides
with the need to preserve a sufficient liver volume to avoid a postoperative hepatic
failure. Currently postoperative liver failure is the major cause of death for these
patients. In the attempt to overcome this limit in the last decades, we tried to
introduce new measures and develop new surgical techniques. From the introduc-
tion by Makuuchi in the 1980s of the preoperative portal embolization, many
surgical techniques have been proposed and perfected. The aim of this chapter is
to describe the new surgical techniques for the approach of complex hepatic
metastases.
Keywords: hepatic liver metastases, hepatectomy, liver failure,
two-stage hepatectomy, ALPPS
1. Introduction
In the recent decades, the improvement of technology associated with a refine-
ment of preoperative imaging allowed to expand surgical indications, leading to
treat patients until a few years ago judged unresectable. These improvements have
made major liver surgery more feasible and sure with a clean reduction of morbidity
and mortality rate. Today after major hepatectomy, mortality ranges from 0.5 and
4%, making surgery a therapeutic option even in case of advanced disease.
Beyond the extension of surgical indications, the pivotal point remains the
possibility to perform a curative resection (R0). Unfortunately, situations such as
chronic liver diseases or an extensive disease do not let to achieve a radical resection
for the inability to maintain a suitable remnant liver after resection for an adequate
postoperative function. Nowadays this is the limits to overcome.
At the current state of knowledge, the future liver remnant (FLR) estimated
before surgical resection should be more of 25% of the total liver volume in patients
without hepatic disease and of around 40% in the patients with history of liver
pathologies (viral chronic hepatitis, alcoholic, nonalcoholic steatohepatitis (NASH),
chemotherapeutic damage).
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An effective and safe surgery can only be achieved with a perfect knowledge of
the surgical anatomy. This anatomy corresponds to a functional liver vascular
distribution based on the concept of the anatomical division of the liver proposed by
Claude Couinaud, Ton That Tung, and Henri Bismuth, which divides the liver into
independent portions that can be handled separately without compromising the
function of the remnant liver.
Unfortunately, today it is not uncommon to evaluate patients at the first
instance inoperable due to the disseminated hepatic spread. The research of new
surgical strategies to effectively extend the number of liver resections and the
concept of “resectability” were one of the biggest challenges in oncologic surgery
over the last 30 years.
To overcome this limit, new surgical techniques have been proposed with the
clear intention of promoting liver regeneration by modifying the procedures first
performed in a single procedure in more steps. Moreover in the case of large and
complex surgical resections, an accurate study of the liver is recommended to
evaluate the postoperative functional reserve with a volumetric and functional
assessment (clearance of indocyanine green, scintigraphy, CT, MR).
Laboratory tests on animals and clinical data showed that the closure of portal
flow toward a hemiliver induces contralateral lobe hypertrophy. Portal flow redis-
tribution can be achieved with surgical ligation (PVL) or percutaneous emboliza-
tion (portal vein embolization (PVE)). The purpose of PVE is to increase
preoperatively the volume of the future remnant liver to allow the surgery and
reduce postoperative morbidity, when the only contraindication to surgery is
represented by the initial insufficient remnant liver. The first to propose this tech-
nique in the 1980s was Makuuchi, and since then huge progress has been made.
Makuuchi and his group [1] first used this technique in 14 patients with cholangio-
carcinoma to minimize the possibility of postoperative hepatic dysfunction. The
results obtained were encouraging without showing major complications and being
able to perform surgical resection in 85% of patients in a timing from 4 to 41 days
after embolization.
The experience of Makuuchi marked a crossroad for the birth of a new surgical
attitude to approach extended right-side hepatectomy, in fact the procedure was
shortly adopted by several surgeons [2–4].
Once the new technique was universally accepted, some surgeons proposed
during the next decade a technical progress describing a sequential surgical proce-
dure called “two-stage hepatectomy (TSH)” [5]. To achieve the goal of radical
resection in patients with colorectal hepatic metastases, the authors outline a previ-
ously therapeutic approach [6]. A procedure includes a first surgical step in which
the removal of the lesions of the left lobe associated with the closure of the right
portal branch is performed. Liver hypertrophy associated with chemotherapy limits
the growth and spread of residual lesions and then allows the patients to undergo
surgery in the absence of disease progression and in the presence of a residual
volume adequate to prevent postoperative hepatic failure. The feasibility of the
procedure was 81% with a mortality rate of 15% for the second stage. At the
beginning the technique did not provide for all patients portal embolization, and
then the routine use of the latter led to a higher rate of hypertrophy and therefore
with a greater rate of patient treated with curative intent [7]. Although the first
results were encouraging, the drawback of TSH led to the impossibility of achieving
sufficient hypertrophy in an acceptable time to avoid a progression of the disease
that in some studies did not allow up to 28% of treated patients to undergo second
surgical phase [8]. The reasons of technique failure were due to disease progression
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inherent to long time to reach the proper hypertrophy or the impossibility to
achieve the desired liver hypertrophy in consideration of the unsuitable size of the
remnant liver.
In the attempt to overcome these limits, in 2012 Schnitzbauer [9] proposed a new
surgical approach, named subsequently by Santibanes [10] “associating liver partition
and portal vein ligation for staged hepatectomy (ALPPS).” The procedure involves
the separation of the future remnant liver from diseased liver through “split” in situ
of the hepatic parenchyma in combination with ligation of the portal vein during
the first phase. Schnitzbauer [9] reported a hypertrophy of the remnant liver
achieved in a very short time (average future remnant liver hypertrophy of 74% in
about 9 days). The mechanism by which ALPPS leads to such a dramatic increase
in hepatic hypertrophy compared to PVE still needs to be fully clarified. Initially it
was thought that the stimulus to hypertrophy was related to the cessation of blood
flow between the diseased segments and the FLR, but some authors have subse-
quently reported how step I in ALPPS leads to an increase in levels of interleukin-6
and tumor necrosis factor-α in liver tissue 1 hour after the procedure compared to
PVL [11]. Therefore, rapid hypertrophy could be associated with a systemic increase
in circulating growth factors as an inflammatory reaction to parenchymal split.
Beyond the first promising results, the high complication rate (44%) with a
mortality of 12% described by Schnitzbauer led to several questions about the role
and indications of the technique in the surgical community. The subsequent expe-
dients to the original technique and the proposal of more restrictive indications
based on practice have led to a significant reduction of the postoperative
morbidity and mortality rate. In fact the results of the most recent ALPPS register
report more encouraging data, with a 90-day mortality of 9% and serious
complications of 27% [12].
Since its introduction until today, under the term ALPPS, many variations and
adaptations of the original technique are grouped. The common thread of all these
variants is to try to reduce morbidity and mortality while maintaining an adequate
hypertrophy response from the liver.
The purpose of the chapter is to analyze which surgical techniques, to date, can
be performed in the presence of diffuse liver metastases.
2. Liver failure
Within this context of extended resection, postoperative liver failure remains a
real concern. The term “small for size syndrome” (SFSS) has been first used in liver
transplantation to describe the development of acute liver failure, situation in which
the donor’s liver was too small for the given recipient. Few years later, Dahm [13]
proposed a systematic definition of SFSS. Small for size syndrome was defined as
the presence of two of the following criteria in the first three postoperative days:
serum bilirubin >6 mg/dL, international normalized ratio (INR) > 2, and the pres-
ence of encephalopathy grade III/IV.
As in liver transplantation, the extension of surgical indications in the presence
of bilobar metastases led to the concept of post-hepatectomy liver failure (PHLF).
PHLF is a clinical manifestation that occurs when the remnant liver is not sufficient
to provide for metabolic demand. To predict early mortality after extensive hepa-
tectomy in 2005, Balzan [14] proposed that the persistence of either PT < 50% or a
serum bilirubin >3 mg/dL on 5 postoperative days is to be considered a predictive
mortality index and indicates PHLF. The result of the study demonstrated that the
3
How to Treat Bilobar Liver Metastases: New Surgical Challenges
DOI: http://dx.doi.org/10.5772/intechopen.86745
conjunction of these two values on 5 postoperative days could predict nearly 100%
morbidity rate and 50% mortality rate.
Recently the International Study Group for Liver Surgery (ISGLS) [15] has
proposed to define PHLF as a “postoperatively acquired deterioration in the ability
of the liver to maintain its synthetic, excretory, and detoxifying functions, charac-
terized by an increased INR and concomitant hyperbilirubinemia on or after post-
operative five days.”
PHLF incidence ranges from 0 to 2% after resection of a healthy liver but can
reach 7% after major hepatectomy. Cirrhotic liver may exceed 30% [16]. PHLF is
the main cause of mortality after extensive hepatic resection, and it may occur even
after the 30th postoperative days [17]. In the last decades, surgical techniques in the
field of hepatic surgery have focus their attention to develop and implement a series
of tools to induce hypertrophy in the future remnant liver to overcome this long-
standing problem.
2.1 Two-stage hepatectomy (TSH)
Patients with disseminated and large liver cancers are one of the major surgical
challenges; two-stage hepatectomy with PVE or PVL, associated by subsequent
hepatectomy, can represent a solution to this dilemma [7].
In the late 1990s, the studies of Bismuth [6] and Azoulay [18] had highlighted
how patients with initially unresectable colorectal liver metastases could benefit by
the use of PVE associated with neoadjuvant chemotherapy. Preoperative treatment
led patients to surgery with survival benefits comparable to those obtained with
primary liver resection (40% patients alive at 5 years).
Whereas not all patients with intrahepatic multinodular liver disease undergoing
portal vein embolization were able to achieve curative surgery, approximately
20 years ago, Adam et al. [5] proposed a new surgical strategy with a possible
curative intent: two-stage hepatectomy “TSH.” They modified this practice by
introducing an initial stage in which in addition to the ligation or portal emboliza-
tion were surgically removed the highest number of metastases but not all of them.
The hepatic hypertrophy and chemotherapy limiting the metastatic diffusion
allowed to perform a second stage for curative purposes reducing the risk of post-
operative hepatic failure (Figure 1). They were the first to report the results of TSH
in terms of feasibility, risks, and patient outcome. The rate of completion of the
procedure was 81% with a survival of 35% at 3 years. The risks related to the
procedure were inherent in the possible tumor progression between the two stages.
But the survival benefit of treated versus untreated patients exceeded methodical
risks. The authors reported a mortality rate of 15% comparable to that of patients
undergoing primary resection during the same period.
Currently TSH is indicated for multiple colorectal liver lesions judged
unresectable in the first instance. As mentioned above the technique provides a first
Figure 1.
Two-stage hepatectomy (surgical steps).
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stage in which the future remnant liver (usually the left lobe) is surgically or by
ablation reclaimed. The first step also provides the execution of PVL or PVE. Portal
occlusion stimulates liver regeneration as the possible growth of occult metastases
in the remnant liver. In fact the possible progression of disease is the main cause
that can prevent the completion of the second surgical phase.
The success of the surgical procedure is closely related to liver regeneration
between the two procedures, which avoids the possible risk of postoperative liver
failure. The rate of liver regeneration is normally assessed through the execution of
a CT scan between 30 and 50 days after the portal occlusion. Although portal
occlusion leads to a higher rate than 40% of liver regeneration, it is not always
possible to reach the second stage of treatment [19]. Disease progression and insuf-
ficient liver regeneration are the main causes leading to a failure of the treatment
that ranges from 22–28% [20]. Patients who do not undergo the second stage have
an extreme unfavorable prognosis compared to patients who complete the treat-
ment. Three and five survival rates were 68% and 49%, respectively, for patients
who underwent second-stage resection and 6 and 0%, respectively, for patients who
did not [21, 22]. Patients enrolled to the second surgery have a median overall
survival of 36 months [23]; these outcomes are comparable with those patients with
resectable colorectal liver metastases at the diagnosis [24–26]. With regard to mor-
bidity and mortality after the first and second stage, in a recent study, Passot [21]
reported a morbidity rate of 26% for the second stage compared to 6% of the first.
Instead the postoperative mortality at 90 days after the second surgery is around
7%, which is halved compared to the data reported by the first studies.
Considering the technique feasible in selected patients with acceptable morbid-
ity and mortality rates, are there selection criteria to select patients? Interesting in
this regard is the paper of Narita [27] which stated that the presence of three or
more metastases in the FLR can be considered a negative prognostic factor. A high
number of metastases in the remnant liver is correlated to an increased possibility of
disease progression during the two surgical stages and may encourage the appear-
ance of “de novo” metastases.
A possible explanation of disease progression, which manifests itself from 13 to
35% of patients [27, 28], is given by numerous experimental studies which
suggested that a hypoxia-induced alteration of tumor microenvironment leads to
an increased production of vascular endothelial growth factors (VEGF), which
can stimulate beyond liver regeneration the growth of dormant
micrometastases [22, 29].
The technique, today, should be considered in selected patients with bilobar
colorectal liver metastases in whom a right hepatectomy would leave more than
three metastases or any metastases of >3 cm in the FLR [30].
Chemotherapy has a key role in the success of sequential treatment. The objec-
tive response to preoperative chemotherapy has been shown to be a strong predic-
tor of survival after resection for colorectal liver metastases [31]. Modern
chemotherapy regimens using a combination of multiple drugs (5-fluorouracil,
oxaliplatin, irinotecan) have achieved really satisfactory results. Some new biologi-
cal agents such as bevacizumab and cetuximab promise to lead to better results [32].
Although the effectiveness of chemotherapy and its execution should be considered
as mandatory for a successful surgical treatment, its use is not without risk. Hepatic
chemotherapy damage expressed in terms of liver steatosis and increased postoper-
ative bleeding should be considered when planning an extensive hepatic resection
[27, 33]. In fact, several studies have shown an increase in mortality in patients
undergoing preoperative chemotherapy.
In conclusion TSH can be considered in selected patients a standard surgical
procedure in the treatment of diffuse liver metastases with an acceptable mortality
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rate. In this regard in fact, a recent study of Baumgart [34] reported a postoperative
30th mortality rate of 0% after the TSH second stage. On the contrary the rate of
completion of the procedure expected at best to be about 80% associated with an
insufficient liver generation reported in some studies [35, 36] can be considered a
technical limit. In combination with failure to achieve an adequate residual liver
volume, disease progression related to the long time needed to achieve liver regen-
eration may be considered the additional limitations of the surgical procedure.
2.2 Associating liver partition and portal vein ligation for two-staged
hepatectomy (ALPPS)
Associating liver partition and portal vein ligation for two-staged hepatectomy
(ALPPS) is a surgical procedure recently introduced in hepatobiliary surgery [9, 10]
which consists of the association, during an initial surgical time, of ligation of the
right portal vein and transection of the hepatic parenchyma in order to induce a rate
of residual liver hypertrophy more marked in a shorter time interval than the
standard techniques (PVE, TSH), and it represented a novel concept and one of the
most promising advances in oncological liver surgery.
The technique, initially described in a single patient with perihilar cholangio-
carcinoma and subsequently tested in a series of patients with diffuse colorectal
liver metastases, involves two separate surgical stages. The new approach described
by Schnitzbauer [9] in 2012 combines in situ split of the liver usually between the
left lateral sector and segment IV° with ligation of the right portal branch followed
by a right or extended right hepatectomy. The removal of the liver metastases in
the left lateral sector can be included in the first surgical stage (Figure 2a, b).
A significant increase in FLR was obtained about 1 week after the first operation,
and in 2 weeks in healthy livers the maximum peak of regeneration is achieved [37].
Schnitzbauer [9] observed features of hepatocyte apoptosis in the diseased liver and
enhanced markers of hepatocyte proliferation in the remnant liver. Although the
precise pathophysiologic mechanism by which this spectacular liver regenerative
response occurs has not yet been clarified in detail, it is thought that the inflamma-
tory response due to the portal ligature associated with the complete hepatic tran-
section, which does not allow cross portal circulation between the two parts of the
liver, is the basis of this regenerative response. The benefits of rapid liver regener-
ation are clear enough to allow the surgeon to complete the procedure in a shorter
time than previous techniques, reducing the risk of possible progression of disease.
Furthermore the advantages are expressed in a shorter period of postoperative
hospital stay for the patient, and from the technical point of view, the surgeons may
be faced with a lower number of postoperative adhesions performing less compli-
cated operations [10].
From the first description of the ALPPS some technical measures have been
introduced. To minimize the possibility of biliary leaks on the surface of the disease
liver, due to ischemia, surgeons placed the latter in a plastic bag with a drain inside;
a catheter was also placed inside the cystic duct to perform a hydraulic test to
highlight any biliary leak in the FLR. They performed, moreover, a portal pedicle
lymphadenectomy, not only for oncological reasons but also for a better identifica-
tion of the hilar structures and portal vein ligation. To facilitate the identification of
hepatic veins, hepatic artery, and portal pedicle at the time of the second operation,
they routinely encircled them with a strong black silk [10]. This new approach
allowed to lead to surgical treatment patients with widespread disease judged
unresectable with the previous techniques.
Beyond the initial enthusiasm for the new surgical procedure, to the detriment
of the latter, the high mortality rate reported in the paper of Schnitzbauer [9]
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generated several controversies in the surgical community. In fact Schnitzbauer
reported a mortality rate of 12% and a morbidity rate of close to 50%.
Over the following years, the technique has been refined trying to better clarify
the indications and the various clinical scenarios, leading to steady improvements
in safety.
During the 12th Biennial Congress of the European-African Hepato-Pancreato-
Biliary Association, in the 10th ALPPS anniversary, some experts discussed indica-
tions, management, mechanisms of regeneration, and the pitfalls of the new
technique [38].
First of all surgeons emphasized how an accurate knowledge of the vascular liver
anatomy (especially that pertaining to the IV° segment [39]) was fundamental to
avoid iatrogenic vascular damage resulting in failure of the procedure. It is neces-
sary to assess liver function in addition to volume to avoid liver postoperative
failure that occurred in 14 and 30% after stages 1 and 2, respectively [40]. The
discrepancy between liver volume increases (up to 200%), and the high rate of liver
failure may be attributed to a lack of maturity of the regenerating hepatocytes [41].
To obtain a proper functional study providing quantitative and visual informa-
tion of the various regional hepatic districts, scintigraphy using 99mTc-labeled
iminodiacetic acid derivatives should be performed. It provides a regional measure
of the function of FLR. The use of scintigraphy for timing of stage 2 in ALPPS was
Figure 2.
ALPPS surgical technique ((a) Removal of the left liver metastases, (b) Parenchymal transection and right
portal branch ligation, step 1; (c) Liver hypertrophy and parenchymal transection, step 2).
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compared with CT volumetry in 60 patients completing ALPPS in six centers. The
results showed that often volumetry overestimated liver function [42].
Some technical aspects to improve ALPPS morbidity have been investigated in
the last years. Interesting are the results of some studies on animal models that have
evidenced as the reduction up to a minimum of 50% of the hepatic transection led
to a rate of regeneration comparable to the complete transection of the parenchyma
[43]. Partial transection offers comparable FLR hypertrophy but significantly lower
morbidity, when compared with total transection (38.1 vs. 88.9%) and near-zero
mortality [44].
Recent studies indicated that the presence of complications after phase 1 is to be
considered predictive of mortality after phase 2 [40]. So during the interstage, the
occurrence of complications is to be decisive for the outcome after ALPPS. In this
respect some limitations in patient selection should be considered: in patients over
65 years of age or with biliary primary disease with associated cholestasis, the
procedure should be contraindicated [43]. International ALPPS registry counts only
11 patients in whom the procedure has been performed for perihilar cholangio-
carcinoma without obtaining encouraging results (90th mortality of 27%) [45].
Most recently, biliary tumors and elevated serum bilirubin (pre-stage 2) were
identified as predictors of futile outcome after ALPPS [43].
With regard to the possible indication of ALPPS for hepatocellular carcinoma,
although the liver’s regenerative capacity is certainly less than a healthy liver [12],
some group experience showed that ALPPS remains a possible approach to
achieving an adequate FLR in patients with hepatitis-related hepatocellular
carcinoma [46].
Colorectal liver metastases represent the main indications of ALPPS. Currently
the mortality of the procedure in patients with colorectal liver metastases stands at
5% with a survival rate at 3 years around 50% [34, 47]. Although the recurrence rate
compared to traditional surgery for colorectal liver metastases is high (only 13% of
3-year-old patients are disease-free), ALPPS is a surgical option for these patients
otherwise unresectable.
As already mentioned the technique has undergone several modifications since
its introduction focused on an attempt to reduce the complications and mortality of
the “classic” ALPPS.
The proposed new technical variations have focused their attention on first-
stage spitting of the liver parenchyma, on the use of ALPPS for salvage or rescue
after TSH, as regard to prevent ischemia of segment IV°, on specific operative
maneuvers (Pringle, hanging, anterior approach), on the use of laparoscopic
approach at either stage, and on the methods to prevent and identify biliary
complications and in the number and position of segments resected [48].
With the term “partial” ALPPS (Figure 3a–d), some authors [44, 49] described
modification, which provided for the partial transection of the entire transection
surface. The latter was carried out from 50–80% of the surface area. The authors
reported no difference in liver hypertrophy between partial and full parenchymal
splitting (60% vs. 61% median FLR hypertrophy), but a much greater morbidity
after the first stage was reported when a full parenchymal split was used.
Associating liver tourniquet and portal ligation for staged hepatectomy (ALTPS).
This technique reported in three studies [50–52] provided the positioning of a
tourniquet around the future line of transection to ensure a parenchymal compres-
sion without having to perform the parenchyma splitting. The authors reported a
median FLR growth of 61% over 7 days and a morbidity of 27 and 36% for stage 1
and stage 2, respectively. But a mortality rate of 9% in their series did not reflect a
real improvement in terms of the patient’s safety. An additional variation indicated
with the name of “sequential” ALTPS was proposed by Robles Campos [50]. Unlike
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the previous, they did not provide the portal ligature but the execution of portal
embolization in the fourth postoperative days. The authors hypothesized that the
delayed cessation of blood flow may be related to a decreased impact and severity of
venous congestion in the FLR, possibly attenuating the risk of postoperative
liver failure.
Conversion to ALPPS appears successful after both PVE and PVL with accept-
able clinical outcomes. No differences in major complications showed by Truant
[53] in patients who had no PVE before an in situ split.
There are also various technical measures proposed to avoid ischemia and the
possible infectious risk at the level of IV° segment, recognized as one of the main
causes of morbidity and mortality during the execution of ALPPS. Systematic use of
antibiotic therapy has been proposed, partial transection was indicated with the role
of generating less ischemic damage [54], and in addition, segment IV° has been
resected [55]. Moreover some authors advise to minimize the surgical manipulation
of the hepatic hilum to avoid hard surgical adhesions and to minimize the tumor
progression during the second phase by means of an anterior approach or Pringle
maneuver [46].
Laparoscopic ALPPS has been successfully performed both for two stages. At the
expense of an increase in technical difficulty, fewer surgical adhesions were
described during the second phase [56]. Although the number of patients treated is
very limited, some series report 0% of mortality rate with no major complications
and with postoperative hospital stay shorter than the open technique [57]. These
results indicate that laparoscopic ALPPS is feasible and it is not inferior to the
open approach.
“Hybrid” ALPPS. The technique consists of three main steps [58]: a surgical
exploration with the parenchymal split in situ using the anterior approach, the
execution of portal embolization using interventional radiology techniques, and
Figure 3.
Surgical steps of laparoscopic “partial ALLPS.” (a) Isolation of the right portal branch. (b) Closing of the right
portal branch with Hem-o-lock. (c) Demarcation of the section line. (d) Parenchymal transection.
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right hepatectomy during the second surgical phase. Special care should be taken
not to dissect the right hepatoduodenal ligament, and right liver mobilization
should not be performed. The technique involves less manipulation to allow more
accurate dissection and a greater oncological effectiveness during the second phase
of the procedure. This approach was proposed for tumors involving biliary conflu-
ence, but although the technique is considered feasible, long-term survival data are
still lacking.
Minimally invasive laparoscopic microwave ablation and portal vein ligation for
staged hepatectomy (LAPS). On the basis that treatment with microwave thermal
ablation/coagulation (MWA) represents a safe and effective treatment option for
primary and metastatic liver malignancy, Gringeri [59] developed a novel ALPPS
variation associating minimally invasive laparoscopic PVL and MWA on the future
transection plane without in situ splitting. This allowed complete and satisfactory
hypertrophy of the nonoccluded FLR (avoiding the development of porto-portal
shunts) and an easier second step (liver resection) in a patient with hepatocellular
carcinoma. With the use of intraoperative laparoscopic ultrasound guidance, the
future transection plane was identified and marked with monopolar cautery. MWA
antenna was then infixed into the parenchyma, positioning it at the right of the
transection plane, applying a 5-minute ablation cycle. This maneuver was repeated
step by step every 3 cm, proceeding from the inferior liver margin to the
suprahepatic veins. This technique creates an avascular separation and a necrotic
groove between the cancer and the FRL in the future transection plane.
Radiofrequency-assisted liver partition with portal vein ligation (RALPP). This
technique first described by Gall [60] uses a radiofrequency ablation device to
create a line of coagulative necrosis in the hepatic parenchyma instead of physical
transection. In experimental study in animals, the procedure has also been
performed percutaneously (percutaneous radiofrequency-assisted liver partition with
portal vein ligation (PRALPPS)) [61].
Although there are still no data on the long-term outcome, as all surgical tech-
niques developed in recent years, they appear to be feasible, inducing a sufficient
hepatic hypertrophy with a lower rate of complications. Their execution, however,
remains limited to highly specialized centers in liver surgery.
3. Conclusion
The improvement of surgical techniques made resectable, in selected cases,
patients with disseminated liver disease, but the treatment of bilobar liver metasta-
ses still remains a surgical challenge. The achievement of an adequate residual liver
volume to avoid postoperative liver failure was a key point of the procedures
developed in recent decades. Since their birth TSH and ALLPS have undergone
several changes in the attempt to reduce the rate of morbidity and mortality, and
giant steps have been taken. The future of this surgery will be surely full of further
innovations and encouraging for hepatobiliary surgeons, never forgetting that a
justified nonoperative approach will always be less invasive than the least invasive
surgical approach.
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